“Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”, J of Skin, vol. 4, no. 6, p. s84, Oct. 2020, doi: 10.25251/skin.4.supp.84.